Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +17.01%
#3 Orochi Network Orochi Network +10.19%
#4 Pump.fun Pump.fun +9.55%
#5 Unit Pump Unit Pump +9.55%
#6 eCash eCash +9.31%
#7 Fake World Assets Fake World Assets +8.82%
#8 OPENLOOT OPENLOOT +8.48%
#9 Meteora Meteora +8.22%
#10 Glidr Glidr +8.12%
Coin of the day
PulseChain PulseChain
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Classement en actions #28040
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Prix de l'action
$0.55
Dernière synchronisation: 2025-02-11
Capitalisation boursière
$28.90M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Marinus Pharmaceuticals, Inc. (MRNS)

Catégorie

Healthcare
Revenus pour Marinus Pharmaceuticals, Inc. (MRNS)
Revenus en Sep 2024 TTM : $31.47M
Selon les derniers rapports financiers de Marinus Pharmaceuticals, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $31.47M. En 2022, l'entreprise a réalisé un chiffre d'affaires de $25.48M une augmentation par rapport à le chiffre d'affaires de l'année 2021, qui était de $15.35M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Marinus Pharmaceuticals, Inc. de 2012 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $31.47M 1.54%
2023 $30.99M 21.63%
2022 $25.48M 66.03%
2021 $15.35M 793.19%
2020 $1.72M 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 $100.00K 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 40,020.45%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 6,980.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 19,035.85%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 49,779.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH